The Paris-based company said it will continue to develop another vaccine candidate that is already undergoing late stage human trials. That...

The design of the Phase 3 study, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate...

The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vac...

The Germany-based BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer, according to a Sa...

The companies said early trials showed the vaccine produced an "insufficient" immune response in older adults, demonstrating the need to re...

Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which th...

Sanofi is working on two vaccine projects to prevent COVID-19 - the illness caused by the new coronavirus - and said it is exploring severa...

Two of the world's largest vaccine manufacturers, Sanofi and GlaxoSmithKline, are coming together to work on a Covid-19 vaccine, which if i...

Phase 3 trials are the last phase of clinical trials that a company conducts before it receives approval to market the drug here.

The ICGEB plans a larger vaccine trial on monkeys in America; the full-fledged human trial after that could cost more than Rs 100 crore.

The decision of the apex committee is expected to delay the entry of the vaccine, which has been approved in Mexico, the Philippines and Br...

Sanofi Pasteur, the vaccines division of Sanofi, today announced launch of ShanIPV, an injectable inactivated polio vaccine (IPV).

Country Head, Sanofi Pasteur, Stephan Barth, said dengue is a serious health concern in India, causing a significant but under-reported bur...

Hyderabad-based Shantha Biotechnics has bagged a USD 340 million (around Rs 1,650 crore) order from Unicef to supply its 'SHAN5', a combina...

The deal between Sanofi its French owners Meriuex Alliance values the unlisted Indian company at Rs 3,740 crore, or about eight times its p...

French pharma major Sanofi-aventis today said its vaccine division Sanofi Pasteur has acquired 80 per cent stake in Shantha Biotechnics for...

India may be a possible location as a global manufacturing base for vaccines business of Sanofi-Aventis Group.